Cancer vaccines for hormone/growth factor immune deprivation: A feasible approach for cancer treatment

Current Cancer Drug Targets

Volumn 7, Issue 3, 2007, Pages 229-241

  Gonzalez G ^a   Lage, A ^a  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

Author keywords

Cancer vaccines; Endocrine therapy; Growth factors; Hormones; Immunotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; AVICINE; CANCER VACCINE; CHORIONIC GONADOTROPIN ANTIBODY; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; FLUOROURACIL; GASTRIMMUNE; GASTRIN; GEFITINIB; GEMCITABINE; GONADIMMUNE; GONADORELIN; INSEGIA; LUTEINIZING HORMONE; NORELIN; PLACEBO; RECOMBINANT EPIDERMAL GROWTH FACTOR; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG;

ABSCESS; ACTIVE IMMUNIZATION; ANTIBODY TITER; ARTICLE; BREAST CANCER; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER SURGERY; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG MEGADOSE; DRUG TARGETING; ENDOMETRIUM CANCER; FEVER; HORMONE DEFICIENCY; HORMONE DEPENDENCE; HORMONE RESPONSE; HUMAN; IMMUNE SYSTEM; INJECTION SITE MYALGIA; INJECTION SITE REACTION; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MONOTHERAPY; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STOMACH CARCINOMA; TUMOR GROWTH; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; AUTOANTIBODIES; CANCER VACCINES; FEASIBILITY STUDIES; HORMONE ANTAGONISTS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASMS;

EID: 34247860903     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800907780618310     Document Type: Article

References (87)

1. Cavalli, F.; Hansen, H. H.; Kaye, S. B. Textbook in Medical Oncology; Third edition. Taylor & Francis Ed., London and New York, 2004.
2. Carpenter, G.; Cohen, S. Epidermal Growth Factor. Ann. Rev. Biochem. 1979, 48, 193-216.
3. Salomon, D. S.; Brandt, R.; Ciardiello, E.; Normanno, N.: Epidermal growth factor derived peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 1995, 19, 183-232.
4. Pavelik, K.; Banjac, Z.; Pavelic, J.; Spaventi, S. Evidence for the role of EGF receptor in the progression of human lung carcinoma. Anticancer Res. 1993, 13, 1133-1137.
5. Bartlett, J. M.; Langdon, S. P.; Simpson, B. J.; Stewart, M.; Katsaros, D.; Sismondi, P. The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Br. J. Cancer 1996, 73, 301-306.
6. Mayer, A.; Takimoto, M.; Fritz, E.; Schellander, G.; Kofler, K.; Ludwing, H. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor and mdr gene expression in colorectal cancer. Cancer 1993, 71, 2454-2460.
7. Grandis, J. R.; Melhem, M. H.; Gooding, W. E.; Day, R.; Holst, V. A.; Wagener, M. M. Levels of TGF alpha and EGFR protein in head and neck squamous cell lung carcinomas and patient survival. J. Natl. Cancer Inst. 1998, 90, 824-832.
8. Ríos, M. A.; Macías, A.; Pérez, R.; Lage, A. Skoog, L. Receptors for epidermal growth factor and estrogen as predictors of relapse in patients with mammary carcinoma. Anticancer Res. 1988, 8, 173-176.
9. Macías, A.; Azavedo, E.; Pérez, R.; Rutquist, L. E.; Skoog, L. Receptors for epidermal growth factor in human carcinomas and their metastases. Anticancer Res. 1986, 6, 849-852.
10. Macías, A.; Azavedo, E.; Hagerstrom, T.; Klintenberg, C.; Pérez, R.; Skoog, L. Prognostic significance of the receptor for epidermal growth factor in human mammary carcinoma. Anticancer Res. 1987, 7, 459-464.
11. Mendelsohn, J. Targeting the Epidermal Growth Factor Receptor for Cancer Therapy. J. Clin. Oncol. 2002, 20(18), 1s-13s.
12. Scheiberg, A. B.; Winkler, M. E.; Derynck, G. Transforming growth factor-alpha: a more potent angiogenic mediator than epidermal growth factor. Science 1986, 232, 1250-1253.
13. Hanahan, D.; Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86, 353-364.
14. Rodríguez, R. P.; Lage, A. Los factores de Crecimiento y sus relaciones con la transformación maligna. Interf. Biotecnol. 1986, 3, 179-209.
15. Lage, A.; Crombet, T.; González, G. Targeting epidermal growth factor receptor signalling: early results and future trends in oncology. Ann. Med. 2003, 35, 327-336.
16. Golsteyn, R. M. Gefitinib does not increase survival in lung cancer patients. Drug Discov. Today 2005, 6, 381.
17. Twombly, R. FDA Oncology Committee debates Iressa's status following negative trial results. J. Nat. Cancer Inst. 2005, 97, 473.
18. Disis, M. L.; Gralow, J. R.; Bernhard, H.; Hand, S. L.; Rubin, W. D.; Cheever, M. A. Peptide-based, but nor whole protein, vaccines elicit immunity to HER-2/neu, an oncogenic self protein. J. Immunol. 1996, 156, 3151-3158.
19. Disis, M. L.; Gooley, T. A. ; Rinn, K. ; Davis, D. ; Piepkorn, M. ; Cheever, M. A. ; Knutson, K. L.; Schiffman, K. Generation of T-cell immunity to the Her-2/neu protein after active immunization with Her-2/neu peptide-based vaccines. J. Clin. Oncol. 2002, 20, 2642-2632.
20. González, G.; Sánchez, B.; Suarez, E.; Beausoleil, I.; Perez, O.; Lastre, M.; Lage, A.. Induction of Immune Recognition of Self Epidermal Growth Factor (EGF): Effect on EGF Biodistribution and Tumor Growth. Vaccine Res. 1996, 5, 233-244.
21. González, G.; Pardo, O. L.; Sánchez, B.; García, J. L.; Beausoleil, I.; Marinello, P.; González, Y.; Domarco, A.; Guillén, G.; Perez, R.; Lage, A. Induction of Immune Recognition of Self Epidermal Growth Factor II: Characterization of the Antibody Response and the Use of a Fusion protein. Vaccine Res. 1997, 6, 91-100.
22. González, G.; Crombet, T.; Catalá, M.; Mirabal, V.; Hernandez, J. C.; González; Y.; Marinello, P.; Guillén, G.; Lage, A. A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial. Ann. Oncol. 1998, 9, 431-435.
23. González, G.; Crombet, T.; Torres, F.; Catalá, M.; Alfonso, L.; Neninger, E.; García, B.; Mulet, A.; Perez, R.; Lage, A. Epidermal growth factor-based cancer vaccine for non-small cell lung cancer therapy. Ann. Oncol. 2003, 14, 461-466.
24. Crombet, T.; Neninger, E.; Catala, M.; García, B.; Leonard, I.; Martínez, L.; González, G.; Pérez, R.; Lage, A. Treatment of NSCLC Patients with an EGF- Based cancer Vaccine. Cancer Biol. Ther. 2006, 5, 145-149.
25. Mulet, A.; Garrido, G.; Alvarez, A.; Menéndez, T.; Bohmer, F. D.; Pérez, R.; Fernández, L. E. The enlargement of the hormone deprivation concept to the blocking of TGFα-autocrine loop: EGFR signalling inhibition. Cancer Immunol. Immunother. 2006, 55, 628-638.
26. Avrameas, S.; Guilbert, B.; Dighiero, G. Natural antibodies against tubulin, actin, myoglobin, thyroglobulin, fetuin, albumin and transferrin are present in normal human sera, and monoclonal immunoglobulins from multiple myeloma and Waldenstrom's macroglobulinemia may express similar antibody specificities. Ann. Immunol. 1981, 132C, 231-236.
27. Cohen, I. R. Regulation of autoimmune disease: physiological and therapeutic. Immunol. Rev. 1986, 94, 5-21.
28. Nikolic-Zugic, J.; Bevan, M. J. Role of self-peptides in positively selecting the T cell repertoire. Nature 1990, 344, 65-67.
29. Pereira, P.; Forni, L.; Larsson, E. L.; Cooper, M.; Heuser, C.; Coutinho, A. Autonomous activation of B and T cells in antigen-free mice. Eur. J. Immunol. 1986, 16, 685-688.
30. Haury, M.; Grandien, A.; Sundblad, A.; Coutinho, A.; Nobrega, A. Global analysis of antibody repertoires. 1. An immunoblot method for the quantitative screening of a large number of reactivities. Scand. J. Immunol. 1994, 39, 79-87.
31. Li, G.; Miles, A.; Line, A.; Rees, R. C. Identification of tumor antigens by serological analysis of cDNA expression cloning. Cancer Immunol. Immunother. 2004, 53, 139-143.
32. Abulafia-Lapid, R.; Elias, D.; Raz, I.; Keren-Zur, Y.; Atlan, H.; Cohen, I. R. T cell proliferative response on type 1 diabetes patients and healthy individuals to human hsp60 and its peptides. J. Autoimun. 1999, 12, 121-129.
33. Burns, J.; Rosenzweig, A.; Xweiman, B.; Lisak, R. P. Isolation of myelin basic protein reactive T-cell lines from normal human blood. Cell Immunol. 1983, 81, 435-440.
34. Petersen, K. G.; Khalaf, A. N.; Naithani, V.; Fabry, M.; Gattner, H. Insulin as a target antigen in autoimmune diabetes: a natural repertoire as the source of antibody response. Acta Diabetol. 1994, 31, 66-72.
35. Ruf, J.; Carayon, P.; Lissitzky, S. Various expressions of a unique anti-human hyroglobulin antibody repertoire in normal state and autoimmune disease. Eur. J. Immunol. 1985, 15, 268-272.
36. Quintana, F. J.; Cohen, I. R. Autoantibody patterns in diabetes-prone NOD mice and in standard C57BL/6 mice. J. Autoimmun. 2001, 17, 191-197.
37. Havran, W. L.; Chien, Y. H.; Allison, J. P. Recognition of self antigens by skin-derived T cells with invariant gamma delta antigen receptors. Science 1991, 252, 1430-1432.
38. Cohen, I. R.; Toung, D. B. Autoimmunity, microbial immunity and the immunological homunculus. Immunol. Today 1991, 12, 105-110.
39. Cohen, I. R. The cognitive paradigm and the immunological homunculus. Immunol. Today 1992, 13, 490-494.
40. Yehuda Shoenfeld. The Decade of Autoimmunity; First edition. Elsevier Sciences & Technology Books, 1999.
41. González, G.; Montero, E.; Leon, K.; Cohen, L. R.; Lage. A. Autoimmunization to Epidermal Growth Factor, a component of the immunological homunculus. Autoimmun. Rev. 2002, 1, 89-95.
42. Burnet, F. M. The concept of immunological surveillance. Prog. Exp. Tumor Res. 1970, 13, 1-27.
43. Thomas, L. On immunosurveillance in human cancer. Yale J. Biol. Med. 1982, 55, 329-333.
44. Dunn, G. P.; Old, L. J.; Schreiber, R. D. The three Es of cancer immunoediting. Ann. Rev. Immunol. 2004, 22, 329-360.
45. Zhang, L.; Conejo-García, J. R.; Katsaros, D.; Gimotty, P. A.; Massobrio, M.; Regnani, G.; Makrigiannakis, A.; Gray, H.; Schienger, K.; Liebam, M. N.; Rubin, S. C.; Coukos, G.. Intratumoral T cells, recurrence, and survival in ephitelial ovarian cancer. N. Engl. J. Med. 2003, 204, 203-213.
46. Nakano, O.; Sato, M.; Naito, Y.; Suzuki, K.; Orikasa, S.; Aizawa, M.; Suzuki, Y.; Shintaku, I.; Nagura, H.; Ohtani, H. Proliferative activity of intratumoral CD8+ T-lymphocutes as a prognostic factor in human renal carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res. 2001, 61, 5132-5136.
47. Naito, Y.; Saito, K.; Shiiba, K.; Ohuchi, A.: Saigenji, K.; Nagura, H.; Ohtani, H. CD8+ T cells infiltrated within cancer cells nests as a prognostic factor in human colorectal cancer. Cancer Res. 1998, 58, 3491-3494.
48. Marrogi, A. J.; Munshi, A.; Merogi, A. J.; Ohadike, Y.; El-Habashi, A.; Marrogi, O. L.; Freeman, S. M. Study of tumor infiltrating lymphocytes nad transforming growth factor-beta as prognostic factors in breast carcinoma. Int. J. Cancer 1997, 74, 492-501.
49. Schumacher, K.; Haensch, W.; Roefzaad, C.; Schlag, P. M. Prognostic significance of activated CD8+ T cell infiltrations within esophageal carcinomas. Cancer Res. 2001, 61, 3932-3936.
50. Sanchez, E. Q.; Marubashi, S.; Jung, G.; Levy, M. F.; Goldstein, R. M.; Molmenti, E. P.; Fasola, C. G.; Gonwa, T. A.; Jennings, L. W.; Brooks, B. K.; Klintmalm, G. B. De novo tumors after liver transplantation: A single institution experience. Liver Transpl. 2002, 8, 285-291.
51. Tenderich, G.; Deyerling, W.; Schulz, U.; Heller, R.; Hornik, L.; Schulze, B.; Jahanyar, J.; Koerfer, R. Malignant neoplastic disorders following long-term immunosuppression after orthotopic heart transplantation. Transplant. Proc. 2001, 33, 3653-3655.
52. Mapara, M. Y.; Sykes, M. Tolerance and cancer: Mechanisms of tumor evasion and strategies for breaking tolerance. J. Clin. Oncol. 2004, 22, 1136-1151.
53. Rosenberg, S. A. Progress in human tumor immunobiology and Immunotherapy. Nature 2001, 411, 380-384.
54. Yu, Z.; Restifo, N. P. Cancer vaccines: progress reveals new complexities. J. Clin. Invest. 2002, 110, 289-294.
55. Mocellin, S.; Mandruzano, S.; Bronte, V.; Lise, M.; Nitti, D. Part I: Vaccines for solid tumors. Lancet Oncol. 2004, 5, 681-689.
56. Berzofsky, J. A.; Terabe, M.; Oh, S.; Belyakov, I. M.; Ahlers, J. D.; Janik, J. E.; Morris, J. C. Progress on new cancer vaccines strategies for the immunotherapy and prevention of cancer. J. Clin. Invest. 2004, 113, 1515-1525.
57. Lage, A.; Pérez, R.; Fernandez, L. E.: Therapeutic Cancer Vaccines: At Midway Between Immunology and Pharmacology. Curr. Cancer Drugs Targets 2005, 5, 611-627.
58. Talwar, G. P.; Sharma, N. C.; Dubey, S. K.; Salahuddin, M.; Das, C.; Ramakrishnan, S.; Kumar, S. Isoimmunization against human chorionic gonadotropin with conjugates of processed β-subunit of the hormone and tetanus toxoid. Proc. Nat. Acad. Sci. USA 1976, 73, 218-222.
59. Talwar, G. P.; Singh, O.; Pal, R.; Chatterjee, N.; Suri, A. K.; Shaha, C. Vaccines for control fertility. Indian J. Exp. Biol. 1992, 30, 947-950.
60. Talwar, G. P. Vaccines for control fertility and hormone-dependent cancers. Immunol. Cell Biol. 1997, 75, 184-189.
61. Triozzi, P. L.; Stevens, V. C. Human chorionic gonadotropin as a target for cancer vaccines. Oncol. Rep. 1999, 6, 7-17.
62. Moulton, H. M.; Yoshihara, P. H.; Mason, D. H.; Iversen, P. L.; Triozzi, P. L. Active specific immunotherapy with a beta-human chorionic gonadotropin peptide vaccine in patients with metastatic colorectal cancer: antibody response is associated with improved survival. Clin. Cancer Res. 2002, 8, 2044-2051.
63. He, L. Z.; Ramakrishna, V.; Connolly, J. E.; Wang, X. T.; Smith, P. A.; Jones, C. L.; Valkova-Valchanova, M.; Arunakumari, A.; Treml, J. F.; Goldstein, J.; Wallace, P. K.; Keler, T.; Endress, M. J. A novel human cancer vaccine elicits cellular response to the tumor-associated antigen, human chorionic gonadotropin beta. Clin. Cancer Res. 2004, 10, 1920-1927.
64. Watson, S.; Durrant, L.; Morris, D. Gastrin : growth enhancing effects on human gastric and colonic tumor cells. Br. J. Cancer 1989, 59, 554-558.
65. Moyer, M. P.; Armstrong, A.; Aust, J. B. Effects of gastrin, glutamine and somatosin on the in vitro growth of normal and malignant human gastric mucosa cells. Arch. Surg. 1986, 121, 285-288.
66. Watson, S. A.; Michaeli, D.; Grimes, S.; Morris, T. M.; Robinson, G.; Varro, A.; Justin, T. A.; Hardcastle, J. D. Gastrimune raises antibodies that neutralize amidated and glycine-extended gastrin-17 and inhibit the tumor growth of colon cancer. Cancer Res. 1996, 15, 880-885.
67. Smith, A. M.; Justin, T.; Michaeli, D.; Watson, A. Phase I/II study of G17-DT, an anti-gastrin immunogen, in advanced colorectal cancer. Clin. Cancer Res. 2000, 6, 4719-4724.
68. Bret, B. T.; Smith, S. C.; Bouvier, C. V.; Michaeli, D.; Hochhauserm, D.; Davidson, B. R. Kurnawinski, T. R.; Watkinson, A. F.; Van Someren, N.; Pounder, R. E.; Caplin, M. E. Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer. J. Clin. Oncol. 2002, 20, 4225-4231.
69. Gillian, A. D.; Watson, S. A.; Henwood, M.; McKenzie, A. J.; Humphreys, J. E.; Elder, J.; Iftikhar, S. Y.; Welch, N.; Fielding, J.; Broome, P.; Michaeli, D. A phase II study of G17DT in gastric carcinoma. Eur. J. Surg. Oncol. 2004, 30, 536-543.
70. Gillian, A. D. Randomized, double blind, placebo-controlled, multicenter, group-sequential trial of G17DT in patients with advanced pancreatic cancer. J. Clin. Oncol. 2004, 22(Suppl.), 2511.
71. Broome, P.; Bruck, R.; Michaeli, D. Immune response to Gastrin-17 as an independent covariate for survival in colorectal, gastric and pancreatic cancers. J. Clin. Oncol. 2004, 22(Suppl.), 4073.
72. Shapiro, J.; Marshall, H.; Karasek, P.; Figer, A.; Oettle, H.; Couture, G.; Jeziorski, K.; Broome, P.; Hawskins R. G17DT + gemcitabine [Gem]versus placebo + Gem in untreated subjects with locally advanced, recurrent or metastatic adenocarcinoma of the pancreas: Results of a rendomized, double-blind, multinational, multicenter study. J. Clin. Oncol. 2005, 23(Suppl.), 1098.
73. Ajani, J. A.; Hecht, J. R.; Ho, L.; Baker, J.; Oorgiesen, M.; Eduljee, A.; Michaeli, D. An Open-Label Multinational, Multicenter Study of G17DT Vaccination Combined with Cisplatin and 5-Fluorouracil in Patients with Untreated, Advanced Gastric or Gastroesophageal Cancer: The GC4 Study. Cancer 2006, 106, 1908-1916.
74. Huggins, C.; Hodges, C. V. Studies in prostatic cancer II: The effect of castration on advanced cancer of the prostate gland. Arch. Surg. 1941, 43, 209-223.
75. Emons, G.; Ortmann, O.; Schulz, K. D.; Schally, A. V. Growth inhibitory actions of analogues of luteinizing hormone releasing hormone on tumor cells. Trends Endocrinol. Metab. 1997, 8, 355-361.
76. Naghton, M.; Picus, J. Advanced prostate cancer. A state-of-the-art guide to pharmacological management. Am. J. Cancer 2002, 1, 13-22.
77. Dreicer, R. Controversies in the systhemic anagement of patients with evidence of biochemical failure following radical prostactectomy. Cancer Treat. Rev. 2002, 28, 189-194.
78. Fuerst, J.; Fiebiger, E.; Jungwirth, A.; Mack, D.; Talwar, G. P.; Frick, J.; Rovan, E. Effect of active immunization against luteinizing hormonereleasing hormone on the androgen-sensitive Dunning R3327-PAP and androgen-independent Dunning R3327-AT2.1 prostate cell lines. Prostate 1997, 32, 77-84.
79. Talwar, G. P. Vaccine for control of fertility and hormone-dependent cancers. Immunol. Cell Biol. 1997, 75, 184-189
80. Simms, M. S.; Scholfield, D. P.; Jacobs, E.; Michaeli, D.; Broome, P.; Humphreys, J. E.; Bishop, M. C. Anti-GnRH antibodies can induce castrate levels of testosterone in patients with advanced prostate cancer. Br. J. Cancer 2000, 83, 443-446.
81. Talwar, G. P.; Singh, O.; Pal, R.; Chattergie, N. Vaccine for control fertility and hormone dependent cancers. Int. J. Immunopharmacol. 1992, 14, 511-514.
82. Talwar, G. P.; Raina, K.; Grupta, J. C.; Ray, R.; Wadhwa, S.; Ali, M. M. A recombinant luteinizing-hormone-releasing-hormone immunogen bioeffective in causing prostatic atrophy. Vaccine 2004, 22, 3713-3721.
83. Parkinson, R. J.; Simms, M.; Broome, P.; Humphreys, J. E.; Bishop, M. C. A vaccination strategy for a long term suppression of androgens in advanced prostate cancer. Eur. Urol. 2004, 45, 171-174.
84. Triozzi, P. L.; Bolger, G. B.; Neidhart, J.; Rinchart, J. J.; Saleh, M.; Allen, K. O.; Sellers, S.; Waddel, M. J. Effect of doxetacel chemotherapy on the activity of a gonadotropin releasing hormone vaccine in patients with advanced prostate cancer. Prostate 2005, 65, 316-321.
85. www.ymbiosciences.com
86. Goronzy, J. J.; Fulbright, J. W.; Crowson, C. S.; Poland, G. A.; O'Fallon, W. M.; Weyand, C. M. Value of immunological markers in predicting responsiveness to influenza vaccination in elderly individuals. Virology 2001, 75, 12182-12187.
87. Linton, P. J.; Dorshkind, K. Age-related changes in lymphocyte development and function. Nat. Immunol. 2004, 5, 133-135.